Tempero Bio

Executive Summary

Tempero Bio is a clinical-stage biopharmaceutical company dedicated to developing small-molecule therapies for substance use disorders (SUDs) and related conditions. Founded in 2020 and headquartered in San Diego, the company aims to address the significant unmet medical need in addiction treatment, a field with limited innovation and high relapse rates. Leveraging expertise in neurobiology and pharmacology, Tempero Bio is advancing a pipeline of novel compounds designed to modulate key neural circuits involved in addiction, thereby reducing cravings and preventing relapse. The company's lead program is currently in Phase 2 clinical development, targeting alcohol use disorder (AUD) and other SUDs. With a strong scientific foundation and a focus on a large, underserved patient population, Tempero Bio is positioned to make a meaningful impact in the addiction space. However, as a private company with limited public data, the risk remains elevated, and near-term value hinges on successful clinical readouts and financing.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 topline data for lead AUD candidate60% success
• H2 2026Series B or C financing round70% success
• Q2 2026FDA feedback on Phase 3 study design or orphan drug designation75% success